Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression

Cell Death and Disease

Volumn 7, Issue 11, 2016, Pages

  Zhu, Jiang ^a,b   Zou, Zhengzhi ^c   Nie, Peipei ^d   Kou, Xiaoni ^e   Wu, Baoyan ^c   Wang, Songmao ^c   Song, Zhangjun ^b   He, Jianjun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Forth Peoples Hospital of Shanxi Province   (China)

^c SOUTH CHINA NORMAL UNIVERSITY   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

^e Affiliated Hospital of Shaanxi College of Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTRADIOL; ESTROGEN; LIVER RECEPTOR HOMOLOG 1; MICRORNA; MICRORNA 27B 3P; TAMOXIFEN; UNCLASSIFIED DRUG; CELL RECEPTOR; CREB1 PROTEIN, HUMAN; MESSENGER RNA; MIRN27 MICRORNA, HUMAN; NR5A2 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOINFORMATICS; BODY WEIGHT; BREAST CANCER; BT-549 CELL LINE; CANCER PATIENT; CANCER RESISTANCE; CANCER TISSUE; CELL VIABILITY; CELL VIABILITY ASSAY; CYTOTOXICITY; DOWN REGULATION; DRUG MEGADOSE; ENZYME ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MCF-10A CELL LINE; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; MOUSE; MTT ASSAY; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SK-BR-3 CELL LINE; STAINING; T-47D CELL LINE; TUMOR CELL; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL SURVIVAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MODELS, BIOLOGICAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85015622723     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.361     Document Type: Article

References (48)

1. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011; 11: 597–608.
2. Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME et al. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast. Clin Cancer Res 2014; 20: 3672–3682.
3. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771–784.
4. Huang B, Warner M, Gustafsson JA. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol 2015; 418(Pt 3): 240–244.
5. Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer 2015; 22: R1–R31.
6. Ma N, Zhang W, Qiao C, Luo H, Zhang X, Liu D et al. The tumor suppressive role of MiRNA-509-5p by targeting FOXM1 in non-small cell lung cancer. Cell Physiol Biochem 2016; 38: 1435–1446.
7. Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF et al. Autophagy-preferential degradation of MIR224 participates in hepatocellular carcinoma tumorigenesis. Autophagy 2014; 10: 1687–1689.
8. Haemmig S, Baumgartner U, Gluck A, Zbinden S, Tschan MP, Kappeler A et al. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis 2014; 5: e1279.
9. Zhang Q, Padi SK, Tindall DJ, Guo B. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis 2014; 5: e1486.
10. Zhang Y, Talmon G, Wang J. MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Cell Death Dis 2015; 6: e1845.
11. Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat 2014; 147: 423–431.
12. Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 2010; 9: 317.
13. Ikeda K, Horie-Inoue K, Ueno T, Suzuki T, Sato W, Shigekawa T et al. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Rep 2015; 5: 13170.
14. Miller T E, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro C et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 44: 29897–29903.
15. Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA, Alahari SK. Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-alpha in breast cancer. Cancer Res 2013; 73: 2884–2896.
16. Chen L, Li H, Han L, Zhang K, Wang G, Wang Y et al. Expression and function of miR-27b in human glioma. Oncol Rep 2011; 26: 1617–1621.
17. Liu F, Zhang S, Zhao Z, Mao X, Huang J, Wu Z et al. MicroRNA-27b up-regulated by human papillomavirus 16 E7 promotes proliferation and suppresses apoptosis by targeting polo-like kinase2 in cervical cancer. Oncotarget 2016; 7: 19666–19679.
18. Lee JJ, Drakaki A, Iliopoulos D, Struhl K. MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 2012; 31: 3818–3825.
19. Takahashi RU, Miyazaki H, Takeshita F, Yamamoto Y, Minoura K, Ono M et al. Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1. Nat Commun 2015; 6: 7318.
20. Thiruchelvam PT, Lai CF, Hua H, Thomas RS, Hurtado A, Hudson W et al. The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat 2011; 127: 385–396.
21. Phuong NT, Lim SC, Kim YM, Kang KW. Aromatase induction in tamoxifen-resistant breast cancer: role of phosphoinositide 3-kinase-dependent CREB activation. Cancer Lett 2014; 351: 91–99.
22. Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y, Hielscher T et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013; 32: 1173–1182.
23. Cui J, Yang Y, Li H, Leng Y, Qian K, Huang Q et al. MiR-873 regulates ERalpha transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene 2015; 34: 4018.
24. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631–643.
25. Liu Y, Cai Q, Bao PP, Su Y, Cai H, Wu J et al. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. Breast Cancer Res Treat 2015; 152: 183–191.
26. Shen S, Sun Q, Liang Z, Cui X, Ren X, Chen H et al. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS One 2014; 9: e100664.
27. Wang Y, Rathinam R, Walch A, Alahari SK. ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J Biol Chem 2009; 284: 23094–23106.
28. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000; 103: 843–852.
29. Zhuo L, Liu J, Wang B, Gao M, Huang A. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013; 29: 555–562.
30. Shang Y, Feng B, Zhou L, Ren G, Zhang Z, Fan X et al. The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer. Oncotarget 2016; 7: 538–549.
31. Lai CF, Flach KD, Alexi X, Fox SP, Ottaviani S, Thiruchelvam PT et al. Co-regulated gene expression by oestrogen receptor alpha and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. Nucleic Acids Res 2013; 41: 10228–10240.
32. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM. Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets 2010; 10: 384–391.
33. Chhabra A, Fernando H, Watkins G, Mansel RE, Jiang WG. Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. Oncol Rep 2007; 18: 953–958.
34. Annicotte JS, Chavey C, Servant N, Teyssier J, Bardin A, Licznar A et al. The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. Oncogene 2005; 24: 8167–8175.
35. Bianco S, Brunelle M, Jangal M, Magnani L, Gevry N. LRH-1 governs vital transcriptional programs in endocrine-sensitive and-resistant breast cancer cells. Cancer Res 2014; 74: 2015–2025.
36. Serasinghe MN, Missert DJ, Asciolla JJ, Podgrabinska S, Wieder SY, Izadmehr S et al. Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance. Oncogene 2015; 34: 857–867.
37. Mueller CR, Roskelley CD. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 2003; 5: 45–52.
38. Shankar DB, Cheng JC, Kinjo K, Federman N, Moore TB, Gill A et al. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 2005; 7: 351–362.
39. Kumar AP, Bhaskaran S, Ganapathy M, Crosby K, Davis MD, Kochunov P et al. Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 2007; 13: 2784–2794.
40. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994; 15: 342–355.
41. Luo X, Yao J, Nie P, Yang Z, Feng H, Chen P et al. FOXM1 promotes invasion and migration of colorectal cancer cells partially dependent on HSPA5 transactivation. Oncotarget 2016; 7: 26480–26495.
42. Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, Tang Z et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy 2012; 8: 1798–1810.
43. Webb R, Wren JD, Jeffries M, Kelly JA, Kaufman KM, Tang Y et al. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1076–1084.
44. Mi YJ, Geng GJ, Zou ZZ, Gao J, Luo XY, Liu Y et al. Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells. PLoS One 2015; 10: e120426.
45. Lou YF, Zou ZZ, Chen PJ, Huang GB, Li B, Zheng DQ et al. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PLoS One 2014; 9: e97719.
46. Jiang S, Zou Z, Nie P, Wen R, Xiao Y, Tang J. Synergistic effects between mTOR complex 1/2 and glycolysis inhibitors in non-small-cell lung carcinoma cells. PLoS One 2015; 10: e132880.
47. Zou ZZ, Nie PP, Li YW, Hou BX, Rui-Li, Shi XP et al. Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. Oncotarget 2015 (e-pub ahead of print 7 Oct 2015; doi:10.18632/oncotarget.5628).
48. Nie P, Hu W, Zhang T, Yang Y, Hou B, Zou Z. Synergistic induction of erlotinib-mediated apoptosis by resveratrol in human non-small-cell lung cancer cells by down-regulating Survivin and up-regulating PUMA. Cell Physiol Biochem 2015; 35: 2255–2271.